LUXMED Sp. z o.o. - Warszawa
- Address
- lock Available on a paid plan
Nervous System Diseases Research
At LUXMED Sp. z o.o. - Warszawa, the clinical trial activity is focused on Nervous System Diseases, with a strong emphasis on generalized Myasthenia Gravis. The studies are designed to assess whether new treatment options can improve daily functioning and overall disease control for people living with this rare neuromuscular condition.
- Evaluating new therapies for generalized Myasthenia Gravis
- Measuring improvements in day-to-day symptoms and functional ability
- Comparing active treatments with placebo to better understand treatment benefit
These trials aim to expand treatment options in neurology by testing whether emerging medicines can provide meaningful relief and better quality of life for patients.
Generalized Myasthenia Gravis Studies
The site in Warsaw is conducting research centered on generalized Myasthenia Gravis, a condition that affects muscle strength and everyday activities. The clinical trials are focused on determining how well investigational therapies may reduce symptom burden and support more stable disease management.
- Testing potential treatments for generalized Myasthenia Gravis
- Assessing changes in patient-reported daily function
- Supporting the development of more effective neuromuscular disease care
Overall, the research at this health care site is aimed at improving treatment effectiveness for patients with this challenging neurological disorder.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Novartis Pharma AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in LUXMED Sp. z o.o. - Warszawa
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase III Randomized, Double-Blind, Placebo-Controlled Study of Iptacopan in Patients with Generalized Myasthenia Gravis | Novartis Pharma AG | Phase III | Recruiting | Sep 2024 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Iptacopan | 1 | Unknown | 2024-09-26 | 2024-09-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.